Retrospective Evaluation of Drug-Drug Interactions With Erlotinib and Gefitinib Use in the Military Health System

Thu-Lan T. Luong; Chelsea N. Powers, PhD; Brian J. Reinhardt, MS; Michael J. McAnulty, PhD; Peter J. Weina, MD; Karen J. Shou, DO; Caban B. Ambar, MS

Background: Erlotinib and gefitinib are epidermal growth factor receptor–tyrosine kinase inhibitors approved for non–small cell lung cancer treatment by the US Food and Drug Administration. Drug-drug interactions (DDIs) with these agents are vague and poorly understood. Because DDIs can have an effect on clinical outcomes, we aimed to identify drugs that interact with erlotinib or gefitinib and describe their clinical manifestations.

Methods: A retrospective analysis was performed on the health records of patients in the US Department of Defense Cancer Registry (retrieved September 2021), Comprehensive Ambulatory/Professional Encounter Records, and Pharmacy Data Transaction Service database (both retrieved May 2022). Patients’ medical history, diagnoses, and demographics were extracted and analyzed for differences in adverse effects when these agents were used alone vs concomitantly with other prescription drugs. Patients’ diagnoses and prescription drug use were extracted to compare completed vs discontinued treatment groups, identify medications commonly co-administered with erlotinib or gefitinib, and evaluate DDIs with antidepressants.

Results: Of 387 patients using erlotinib, 264 completed treatments; 28 of 33 patients using gefitinib completed treatment. The P value for erlotinib discontinuation when used alone vs concomitantly was < .001, and the P value for gefitinib discontinuation was .06. Patients who took erlotinib or gefitinib concomitantly with a greater number of prescription drugs had a higher rate of treatment discontinuation than those who received fewer medications. Patients in the completed group received 1 to 75 prescription drugs, and those in the completed group were prescribed 3 to 103. Those who discontinued treatment had more diagnosed medical issues than those who completed treatment.

Conclusions: This review cannot conclude that concomitant use with prescription drug(s) resulted in erlotinib or gefitinib discontinuation. There were no significant DDIs determined between erlotinib or gefitinib and antidepressants.
compliance with the Health Insurance Portability and Accountability Act as an exempt protocol. The Joint Pathology Center of the US Department of Defense (DoD) Cancer Registry and MHS data experts from the Comprehensive Ambulatory/Professional Encounter Record (CAPER) and the Pharmacy Data Transaction Service (PDTS) provided data for the analysis.

**METHODS**

The DoD Cancer Registry Program was established in 1986 by the Assistant Secretary of Defense for Health Affairs. The registry currently contains data from 1998 to 2023. CAPER and PDTS are part of the MHS Data Repository/Management Analysis and Reporting Tool database. Each observation in the CAPER record represents an ambulatory encounter at a military treatment facility (MTF). CAPER records are available from 2003 to 2023.

Each observation in the PDTS record represents an outpatient prescription filled for an MHS beneficiary at MTFs through the TRICARE mail-order program or a retail pharmacy in the United States. Missing from this record are prescriptions filled at civilian pharmacies outside the United States and inpatient pharmacy prescriptions. The MHS Data Repository PDTS record is available from 2002 to 2023. The Composite Health Care System—the legacy system—is being replaced by GENESIS at MTFs.

**Data Extraction Design**

The study design involved a cross-sectional analysis. We requested data extraction for erlotinib and gefitinib from 1998 to 2021. Data from the DoD Cancer Registry were used to identify patients who received cancer treatment. Once patients were identified, the CAPER database was searched for diagnoses to identify other health conditions, while the PDTS database was used to populate a list of prescription medications filled during chemotherapy treatment.

Data collected from the Joint Pathology Center included cancer treatment (alone or concomitant), cancer information (cancer types and stages), demographics (sex, age at diagnosis), and physicians’ comments on AEs. Collected data from the MHS include diagnosis and filled prescription history from initiation to completion of the therapy period (or a buffer of 6 months after the initial period). We used all collected data in this analysis. The only exclusion criterion was a provided physician’s note commenting that the patient did not use erlotinib or gefitinib.

**Data Extraction Analysis**

The Surveillance, Epidemiology, and End Results Program Coding and Staging Manual 2016 and the *International Classification of Diseases for Oncology (ICD-O)* were used to decode disease and cancer types. Data sorting and analysis were performed using Microsoft Excel. The percentage for the total was calculated by using the total number of patients or data available within the gefitinib and erlotinib groups divided by total number of patients or data variables. The subgroup percentage was calculated by using the number of patients or data available within the subgroup divided by the total number of patients in that subgroup.

In alone vs concomitant and completed vs discontinued treatment groups, a 2-tailed, 2-sample z test was used to calculate *P* to determine statistical significance (*P* < .05) using a statistics website. Concomitant was defined as erlotinib or gefitinib taken with other medication(s) before, after, or at the same time as cancer therapy. For the retrospective data analysis, physicians’ notes with “,” “,” “/”, “;”, (period, comma, forward slash, semicolon) or space between medication names were interpreted as concurrent, while “+”, “-/+” (plus, minus/plus), or and between drug names were interpreted as combined. Completed treatment was defined as erlotinib or gefitinib as the last medication the patient took without recorded AEs; switching or experiencing AEs was defined as discontinued treatment.

**RESULTS**

**Erlotinib**

The Joint Pathology Center provided 387 entries for 382 patients aged 21 to 93 years (mean, 65 years) who were treated systemically with erlotinib from January 1, 2001, to December 31, 2020. Five patients had duplicate entries because they had different cancer sites. There were 287 patients (74%) with lung cancer, 61 (16%) with pancreatic cancer, and 39 (10%) with other cancers. For lung cancer, there were 118 patients (30%) for the upper lobe, 78 (20%) for the lower lobe, and 60 (16%) not otherwise
Drug Interactions

specified (NOS). Other lung cancer sites had fewer patients: 21 (5%) middle lobe lung, 6 (2%) overlapping lung lesion(s), and 4 (1%) main bronchus of the lung. For pancreatic cancer, there were 27 patients (7%) for the head of the pancreas, 10 (3%) pancreas NOS, 9 (2%) body of the pancreas, 9 (2%) tail of the pancreas, 4 (1%) overlapping lesions of the pancreas, 1 (< 1%) pancreatic duct, and 1 (< 1%) other specified parts of the pancreas. Thirty-nine patients (10%) received erlotinib for indications that were not for FDA-approved indications, which included 9 (2%) for kidney NOS, 8 (2%) for the unknown primary site, 5 (1%) for liver cancer, 2 (1%) for intrahepatic bile duct, 2 (1%) for tonsil, and 1 (< 1%) for 13 disease sites (Table 1).

<table>
<thead>
<tr>
<th>Cancer Location</th>
<th>Erlotinib, No. (%)</th>
<th>Gefitinib, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>287 (74)</td>
<td>31 (94)</td>
</tr>
<tr>
<td>Upper lobe</td>
<td>118 (30)</td>
<td>14 (42)</td>
</tr>
<tr>
<td>Lower lobe</td>
<td>78 (20)</td>
<td>8 (24)</td>
</tr>
<tr>
<td>Lung NOS</td>
<td>60 (16)</td>
<td>6 (18)</td>
</tr>
<tr>
<td>Middle lobe</td>
<td>21 (5)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Overlapping lesion</td>
<td>6 (2)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Main bronchus</td>
<td>4 (1)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Pancreatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>61 (16)</td>
<td>—</td>
</tr>
<tr>
<td>Head of the pancreas</td>
<td>27 (7)</td>
<td>—</td>
</tr>
<tr>
<td>Pancreas NOS</td>
<td>10 (3)</td>
<td>—</td>
</tr>
<tr>
<td>Body of the pancreas</td>
<td>9 (2)</td>
<td>—</td>
</tr>
<tr>
<td>Tail of pancreases</td>
<td>9 (2)</td>
<td>—</td>
</tr>
<tr>
<td>Overlapping lesions of pancreases</td>
<td>4 (1)</td>
<td>—</td>
</tr>
<tr>
<td>Pancreatic duct</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Other specified parts of pancreas</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>39 (10)</td>
<td>2 (6)</td>
</tr>
<tr>
<td>Kidney NOS</td>
<td>9 (2)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Unknown primary site</td>
<td>8 (2)</td>
<td>—</td>
</tr>
<tr>
<td>Liver cancer</td>
<td>5 (1)</td>
<td>—</td>
</tr>
<tr>
<td>Intrahepatic bile duct</td>
<td>2 (1)</td>
<td>—</td>
</tr>
<tr>
<td>Tonsil</td>
<td>2 (1)</td>
<td>—</td>
</tr>
<tr>
<td>Axillary tail of the breast</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Breast NOS</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Cardia, NOS gastric stomach</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Eye, NOS</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Lower third of the esophagus</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Ovary</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Parietal lobe</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Pleura, NOS (heart, mediastinum)</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Pyriform sinus</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Supraglottis (larynx-vocal cord)</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Temporal lobe</td>
<td>1 (&lt; 1)</td>
<td>—</td>
</tr>
<tr>
<td>Thyroid gland</td>
<td>—</td>
<td>1 (&lt; 1)</td>
</tr>
</tbody>
</table>

Abbreviation: NOS, not otherwise specified.


There were 342 patients (88%) who were aged > 50 years; 186 male patients (48%) and 201 female patients (52%). There were 293 patients (76%) who had a cancer diagnosis of stage III or IV disease and 94 (24%) who had a cancer diagnosis of stage ≤ II (combination of data for stage 0, 1, and 2, not applicable, and unknown). For their systemic treatment, 161 patients (42%) were treated with erlotinib alone and 226 (58%) received erlotinib concomitantly with additional chemotherapy. Of these patients, 287 (74%) were diagnosed with lung cancer (Table 2).

Patients were more likely to discontinue erlotinib for chemotherapy if they received concomitant treatment. Among the patients receiving erlotinib monotherapy, 5% stopped the treatment, whereas 51% of patients treated concomitantly discontinued (P < .001). The comparisons for lung cancer vs other cancer and those aged ≤ 50 years vs > 50 years were significant.
Drug Interactions

Among the 123 patients who discontinued their treatment, 101 switched treatment with no AEs notes, 22 died or experienced fatigue with blurry vision, constipation, nonspecific gastrointestinal effects, grade-4 diarrhea (as defined by the Common Terminology Criteria for Adverse Events), or developed a pleural fluid, pneumonitis, renal failure, skin swelling and facial rash, and unknown AEs of discontinuation. Patients who discontinued treatment because of unknown AEs had physicians’ notes that detailed emergency department visits, peripheral vascular disease, progressive disease, and treatment cessation, but did not specify the exact symptom(s) that led to discontinuation. The causes of death are unknown because they were not detailed in the available notes or databases. The overall results in this retrospective review cannot establish causality between taking erlotinib or gefitinib and death.

**Gefitinib**

In September 2021, the Joint Pathology Center provided 33 entries for 33 patients who were systemically treated with gefitinib from January 1, 2002, to December 31, 2017. The patient ages ranged from 49 to 89 years with a mean age of 66 years. There were 31 (94%) and 2 (6%) patients with lung and other cancers, respectively. The upper lobe, lower lobe, and lung NOS had the most patients: 14 (42%), 8 (24%), and 6 (18%), respectively. There were 31 patients (94%) who were aged > 50 years; 15 were male (45%) and 18 were female (55%). There were 26 patients (79%) who had a cancer diagnosis of stage III

<table>
<thead>
<tr>
<th>TABLE 2 Military Health System Cancer Registry Database</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary analysis</strong></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Treatment</td>
</tr>
<tr>
<td>Alone</td>
</tr>
<tr>
<td>Concomitant</td>
</tr>
<tr>
<td>Cancers</td>
</tr>
<tr>
<td>Lung cancer</td>
</tr>
<tr>
<td>Others</td>
</tr>
<tr>
<td>Stages ≤ II</td>
</tr>
<tr>
<td>Stages III &amp; IV</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>≤ 50 y</td>
</tr>
<tr>
<td>&gt; 50 y</td>
</tr>
<tr>
<td>Subgroup analysis</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>Treatment</td>
</tr>
<tr>
<td>Alone</td>
</tr>
<tr>
<td>Concomitant</td>
</tr>
<tr>
<td>Cancers</td>
</tr>
<tr>
<td>Lung cancer</td>
</tr>
<tr>
<td>Others</td>
</tr>
<tr>
<td>Stages ≤ II</td>
</tr>
<tr>
<td>Stages III &amp; IV</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>≤ 50 y</td>
</tr>
<tr>
<td>&gt; 50 y</td>
</tr>
</tbody>
</table>

Abbreviation: AE, adverse event.

\( P = .005 \) and .05, respectively) while other comparisons were not significant (Table 3).

...
Drug Interactions

or IV disease. Nineteen patients (58%) were treated with gefitinib alone, and 14 (42%) were treated with gefitinib concomitantly with additional chemotherapy. Thirty-one patients (94%) were treated for lung cancer (Table 2). Thirty-three patients are a small sample size to determine whether patients were likely to stop gefitinib if used concomitantly with other drugs. Among the patients treated with gefitinib monotherapy, 5% (n = 1) stopped treatment, whereas 29% (n = 4) of patients treated concomitantly discontinued treatment (P = .06). All comparisons for gefitinib yielded insignificant P values. Physicians’ notes indicated that the reasons for gefitinib discontinuation were life-altering pruritis and unknown (progressive disease outcome) (Table 3).

### Management Analysis and Reporting Tool Database

MHS data analysts provided data on diagnoses for 348 patients among 415 submitted treatment groups. Each patient had 1 to 104 completed (completed treatment group) and 1 to 157 unique health conditions documented. The MHS reported 1319 unique diagnosis conditions for the completed group and 1266 for the discontinued group. Patients with additional health issues stopped chemotherapy use more often than those without; P < .001 for the completed group (232 patients, 1319 diagnoses) vs the discontinued group (112 patients, 1266 diagnoses). The mean (SD) number of diagnoses was 19 (17) for the completed and 30 (22) for the discontinued treatment groups (Figure). The 5 most recorded diagnoses with erlotinib among 358 patients were malignant neoplasm of bronchus and lung for 225 patients, unspecified essential hypertension for 120 patients, encounters for antineoplastic chemotherapy for 113 patients, dietary

### TABLE 3 AE-Related Discontinuations

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Erlotinib, AEs/patients (%)</th>
<th>Geftinib, AEs/patients (%)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alone</td>
<td>8/161 (5)</td>
<td>1/19 (5)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Concomitant</td>
<td>115/226 (51)</td>
<td>4/14 (29)</td>
<td>.06</td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung cancer</td>
<td>80/287 (28)</td>
<td>4/31 (13)</td>
<td>.005</td>
</tr>
<tr>
<td>Others</td>
<td>43/100 (43)</td>
<td>1/2 (50)</td>
<td>.16</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ II</td>
<td>32/94 (34)</td>
<td>1/7 (14)</td>
<td>.59</td>
</tr>
<tr>
<td>III &amp; IV</td>
<td>91/293 (31)</td>
<td>4/22 (10)</td>
<td>.81</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>55/186 (30)</td>
<td>1/15 (7)</td>
<td>.37</td>
</tr>
<tr>
<td>Female</td>
<td>68/201 (34)</td>
<td>4/18 (22)</td>
<td>.21</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 50 y</td>
<td>20/45 (44)</td>
<td>0/2 (0)</td>
<td>.05</td>
</tr>
<tr>
<td>&gt; 50 y</td>
<td>103/342 (30)</td>
<td>5/31 (16)</td>
<td>.54</td>
</tr>
</tbody>
</table>

Abbreviation: AE, adverse event.

*P values calculated with 2-tailed, 2-sample z test between groups: alone vs concomitant, lung vs other cancers, stages ≤ II vs III & IV, male vs female, and ≤ 50 y vs > 50 y.

or IV disease. Nineteen patients (58%) were treated with gefitinib alone, and 14 (42%) were treated with gefitinib concomitantly with additional chemotherapy. Thirty-one patients (94%) were treated for lung cancer (Table 2). Thirty-three patients are a small sample size to determine whether patients were likely to stop gefitinib if used concomitantly with other drugs. Among the patients treated with gefitinib monotherapy, 5% (n = 1) stopped treatment, whereas 29% (n = 4) of patients treated concomitantly discontinued treatment (P = .06). All comparisons for gefitinib yielded insignificant P values. Physicians’ notes indicated that the reasons for gefitinib discontinuation were life-altering pruritis and unknown (progressive disease outcome) (Table 3).

### Management Analysis and Reporting Tool Database

MHS data analysts provided data on diagnoses for 348 patients among 415 submitted treatment groups. Each patient had 1 to 104 completed (completed treatment group) and 1 to 157 unique health conditions documented. The MHS reported 1319 unique diagnosis conditions for the completed group and 1266 for the discontinued group. Patients with additional health issues stopped chemotherapy use more often than those without; P < .001 for the completed group (232 patients, 1319 diagnoses) vs the discontinued group (112 patients, 1266 diagnoses). The mean (SD) number of diagnoses was 19 (17) for the completed and 30 (22) for the discontinued treatment groups (Figure). The 5 most recorded diagnoses with erlotinib among 358 patients were malignant neoplasm of bronchus and lung for 225 patients, unspecified essential hypertension for 120 patients, encounters for antineoplastic chemotherapy for 113 patients, dietary

### TABLE 3 AE-Related Discontinuations

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Erlotinib, AEs/patients (%)</th>
<th>Geftinib, AEs/patients (%)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alone</td>
<td>8/161 (5)</td>
<td>1/19 (5)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Concomitant</td>
<td>115/226 (51)</td>
<td>4/14 (29)</td>
<td>.06</td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lung cancer</td>
<td>80/287 (28)</td>
<td>4/31 (13)</td>
<td>.005</td>
</tr>
<tr>
<td>Others</td>
<td>43/100 (43)</td>
<td>1/2 (50)</td>
<td>.16</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ II</td>
<td>32/94 (34)</td>
<td>1/7 (14)</td>
<td>.59</td>
</tr>
<tr>
<td>III &amp; IV</td>
<td>91/293 (31)</td>
<td>4/22 (10)</td>
<td>.81</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>55/186 (30)</td>
<td>1/15 (7)</td>
<td>.37</td>
</tr>
<tr>
<td>Female</td>
<td>68/201 (34)</td>
<td>4/18 (22)</td>
<td>.21</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 50 y</td>
<td>20/45 (44)</td>
<td>0/2 (0)</td>
<td>.05</td>
</tr>
<tr>
<td>&gt; 50 y</td>
<td>103/342 (30)</td>
<td>5/31 (16)</td>
<td>.54</td>
</tr>
</tbody>
</table>

Abbreviation: AE, adverse event.

*P values calculated with 2-tailed, 2-sample z test between groups: alone vs concomitant, lung vs other cancers, stages ≤ II vs III & IV, male vs female, and ≤ 50 y vs > 50 y.
TABLE 4 Medications That Could Inhibit and Induce Effects on Cytochrome P450 Isoenzymes and Metabolism Pathways Observed Among Patients Experiencing Adverse Events With Erlotinib or Gefitinib

<table>
<thead>
<tr>
<th>Type</th>
<th>Drug name (No./adverse events)*</th>
<th>Might inhibit/induce cytochrome P450</th>
<th>Metabolized by cytochrome P450</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>Erlotinib (240/13)</td>
<td>Inhibit: 1A1 (potent/strong), 3A4, 2C8 (moderate)</td>
<td>3A4, 3A5, 2D6, 1A1, 1A2, 2C9, 2C19</td>
</tr>
<tr>
<td></td>
<td>Capecitabine (19/2)†</td>
<td>Unknown/not reported</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Carboplatin (20/1)</td>
<td>Unknown/not reported</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Gefitinib (18/1)‡</td>
<td>Inhibit: 2C19, 2D6 (weak/mild), 1A2, 2C9, 3A4 (minimal/none)</td>
<td>3A4, 3A5, 2D6, 1A2, 1A1, 1B1, 2C8, 2C9</td>
</tr>
<tr>
<td></td>
<td>Gemcitabine (16/2)§</td>
<td>Unknown/not reported</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Megestrol (66/1)</td>
<td>Unknown/not reported</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Paclitaxel (11/1)</td>
<td>Unknown/not reported</td>
<td>2C8, 3A4</td>
</tr>
<tr>
<td></td>
<td>Pemetrexed (18/1)</td>
<td>Unknown/not reported</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Osimertinib (6/1)</td>
<td>Inhibit: 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 (minimal/none)</td>
<td>3A4, 3A5, 2D6, 1A2 (weak/mild)</td>
</tr>
</tbody>
</table>

| Antidepressants | Amitriptyline (6/1)            | Unknown/not reported                  | 1A2, 2D6, 3A4, 2C19            |
|                 | Escitalopram (5/0)             | Inhibit: 2D6 (weak/mild), 3A4, -1A2, -2C9, -2C19, 2E1 (minimal/none) | 3A4, 2C19, 2C6, 1A2, 2C9, 3A4 |
|                 | Mirtazapine (11/1)             | 2D6, 3A4, 1A2 (weak/mild)             | 2D6, 1A2, 3A4                  |
|                 | Paroxetine (5/1)               | Inhibit: 2D6 (potent/strong), 1A2, 2C9, 2C19, 3A4 (weak/mild) | 2D6, 3A4, 2C9                 |
|                 | Trazodone (8/1)                | Unknown/not reported                  | 3A4                           |
|                 | Venlafaxine (15/1)             | Inhibit: 2D6, 3A4 (weak/mild), 1A2, 2C9, 2C19 (minimal/none) | 2D6, 2C9                       |

| Noncancer       | Ondansetron (151/10)           | Inhibit and induce: 1A2, 2D6, 3A4 (none) | 3A4, 1A2, 2D6                  |
|                | Dexamethasone (119/9)          | Induce: 3A4 (weak/mild)                | 3A4                           |
|                | Levofloxacin (60/11)           | Unknown/not reported                   | —                             |
|                | Oxycodone-acetaminophen (71/8) | Unknown/not reported                   | 3A4, 2D6, 2E1, 1A2            |
|                | Docusate (96/7)                | Unknown/not reported                   | —                             |
|                | Polyethylene glycol (60/8)     | Unknown/not reported                   | —                             |
|                | Azithromycin (30/5)            | Unknown/not reported                   | —                             |
|                | Acetaminophen (53/6)           | Unknown/not reported                   | 2E1                           |
|                | Prochlorperazine (105/5)       | Unknown/not reported                   | —                             |
|                | Prednisone (43/6)§             | Unknown not reported                   | —                             |
|                | Hydrocortisone (59/5)         | Unknown/not reported                   | —                             |

*In the parentheses, the numerator represent the total number of patients who filled that medication and the denominator is the number of patients who experienced recorded adverse events while taking both that medication and erlotinib or gefitinib.
†Major pathways.
‡Cancer drugs used in combination with erlotinib.
§Patients experience adverse effects while receiving erlotinib or gefitinib treatment, while other drug patients experience adverse effects while receiving erlotinib treatment.

surveillance and counseling for 102 patients, and unspecified administrative purposes for 97 patients.

MHS data was provided for patients who filled erlotinib (n = 240) or gefitinib (n = 18). Among the 258 patients, there were 179 and 79 patients in the completed and discontinued treatment groups, respectively. Each patient filled 1 to 75 (for the completed treatment group) and 3 to 103 (for the discontinued treatment group) prescription drugs. There were 805 unique-filled prescriptions for the completed
and 670 for the discontinued group. Patients in the discontinued group filled more prescriptions than those who completed treatment; \(P < .001\) for the completed group (179 patients, 805 drugs) vs the discontinued group (79 patients, 670 drugs).

The mean (SD) number of filled prescription drugs was 19 (11) for the completed group and 29 (18) for the discontinued treatment group. The 5 most filled prescriptions with erlotinib from 258 patients with PDTS data were ondansetron (151 prescriptions, 10 recorded AEs), dexamethasone (119 prescriptions, 9 recorded AEs), prochlorperazine (105 prescriptions, 15 recorded AEs), oxycodone (99 prescriptions, 1 AE), and docusate (96 prescriptions, 7 recorded AEs).

**DISCUSSION**

The difference between erlotinib and gefitinib data can be attributed to the FDA approval date and gefitinib’s association with a higher frequency of hepatotoxicity.\(^{18-20}\) The FDA designated gefitinib as an orphan drug for EGFR mutation–positive NSCLC treatment. Gefitinib first received accelerated approval in 2003 for the treatment of locally advanced or metastatic NSCLC. Gefitinib then was voluntarily withdrawn from the market following confirmatory clinical trials that did not verify clinical benefit.

The current approval is for a different patient population—previously untreated, metastatic EGFR exon 19 or 21 L858R mutation—than the 2003 approval.\(^5,6\) There was no record of gefitinib use after 2017 in our study.

Erlotinib is a reversible EGFR-TKI that is approved by the FDA as first-line (maintenance) or second-line treatment (after progression following at least 1 earlier chemotherapy regimen) for patients with metastatic NSCLC who harbor EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\(^3\) Since 2005, the FDA also approved erlotinib for first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer in combination with gemcitabine.\(^3\) Without FDA indication, erlotinib is used for colorectal, head and neck, ovarian carcinoma, pancreatic carcinoma, and breast cancer.\(^21\)

Erlotinib and gefitinib are not considered first-line treatments in EGFR exon 19 or 21–mutated NSCLC because osimertinib was approved in 2018. Targeted therapies for EGFR
mutation continue to advance at a fast pace, with amivantamab and mobocertinib now FDA approved for EGFR exon 20 insertion–mutated NSCLC.

**Erlotinib Use**

Thirty-nine patients (10%) in this study were prescribed erlotinib for off-label indications. Erlotinib was used alone or in combination with bevacizumab, capecitabine, cisplatin, denosumab, docetaxel, gemcitabine, and the MEK-inhibitor selumetinib. Erlotinib combined with cisplatin, denosumab, docetaxel, and gemcitabine had no recorded AEs, with 10 data entries for gemcitabine and 1 for other drugs. Three patients received bevacizumab and erlotinib, and 1 patient (diagnosed with kidney NOS) showed rash or facial swelling/erythema and diffuse body itching then stable disease after 2 cycles.

One patient (diagnosed with cancer located at the pancreas head) was bridged with capecitabine and erlotinib when going on a vacation, then received FOLFIRINOX (a combination chemotherapy regimen containing folinic acid [leucovorin], fluorouracil, irinotecan, and oxaliplatin), which led to significant fatigue, blurry vision, and constipation. One patient was treated for lung NOS with the MEK-inhibitor selumetinib plus erlotinib and developed pneumonitis following treatment.

Because oncologists followed guidelines and protocols in systemic treatment, DDIs of erlotinib concurrently (before or after) and in combination with cancer drugs were unlikely. Further investigation is needed for several 1:1:1 DDIs with noncancer drugs. A retrospective overview is not a randomized clinical study; therefore, analysis is limited. Data from the MHS were obtained solely from notes from physicians who treated the patients; therefore, exact information explaining whether a patient completed treatment or had to withdraw could not be extrapolated (ie, blood/plasma samples were not obtained to confirm).

**Discontinued Treatment**

The reasons for treatment discontinuation with erlotinib or gefitinib varied among patients, with no consistent AE or cause. Most data were for switching treatments after discontinuing treatment with erlotinib (101 of 123 patients) and gefitinib (2 of 5 patients). This is not surprising given the widely recognized pillars of therapy for NSCLC: chemotherapy, target therapy, and immunotherapy. From the MHS records, the reasons patients switched treatment of erlotinib or gefitinib were not listed or listed as due to negative EGFR testing, lack of responsiveness, or enrollment in a different treatment.

Physicians’ notes on AEs were not detailed in most cases. Notes for gastrointestinal effects, life-altering pruritis, intolerance, peripheral vascular disease, pneumonitis, and progressive disease described the change in status or appearance of a new medical condition but did not indicate whether erlotinib or gefitinib caused the changes or worsened a pre-existing condition.

The causes of AEs were not described in the available notes or the databases. This retrospective data analysis only focused on identifying drugs involved with erlotinib and gefitinib treatment; further mapping of DDIs among patients experiencing AEs needs to be performed, then in vitro data testing before researchers can reach a conclusion.

**DDIs With Antidepressants**

We used the PDTS database to evaluate patients who experienced AEs, excluding patients who switched treatment. Thirteen patients filled a prescription for erlotinib and reported taking 220 cancer and noncancer prescription drugs. One patient (pruritis) was taking gefitinib along with 16 noncancer prescription drugs. Table 4 details CYP information for cancer drugs, antidepressants, and noncancer drugs (top 11 drugs) among patients who recorded AEs with erlotinib.

Selective serotonin reuptake inhibitors and other antidepressants have been implicated in CYP 2D6 inhibition and DDIs. Losartan is a widely used antihypertensive drug with a favorable DDI profile. Erlotinib and gefitinib are primarily metabolized via CYP 2D6 and 3A4 pathways. DDIs from in vitro human hepatocytes assays revealed that gefitinib had significant metabolic changes in a 1:1 (P < .05) combination with paroxetine or sertraline, and a 1:1:1 combination with losartan and fluoxetine, fluvoxamine, paroxetine, or sertraline. Citalopram and venlafaxine seemed to be unaffected by any combination (P ≥ .05). Erlotinib with fluoxetine or losartan 1:1 yielded insignificant differences in metabolism for all drugs (P ≥ .05). Three drug combinations of 1:1:1 involving fluoxetine and losartan with
erlotinib yielded significant degrees of inhibition of fluoxetine and losartan metabolism (\(P < .05\)) but not erlotinib.52

Our data showed that 16 antidepressants (amitriptyline, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, imipramine, fluoxetine, fluvoxamine, mirtazapine, nortriptyline, paroxetine, phenelzine, sertraline, trazodone, and venlafaxine) were recorded with concomitant erlotinib or gefitinib from initiation to completion of therapy or a buffer of 6 months from the first diagnosis date. Based on the date dispensed and days’ supply, only escitalopram could be used in combination with gefitinib treatment. The one patient who filled a prescription for gefitinib and escitalopram completed treatment without recorded AEs. PDTS database confirmed that patients experienced AEs with 5 antidepressants (amitriptyline, mirtazapine, paroxetine, trazodone, and venlafaxine) with concomitant erlotinib use.

Based on the date dispensed and days’ supply, only trazodone could be used in combination with erlotinib. PDTS database showed that cancer drugs (erlotinib and megestrol) and 39 noncancer drugs (including acetaminophen, azithromycin, dexamethasone, hydrocortisone, and polyethylene glycol) were filled by 1 patient whose physician noted skin rash. Another limitation of using databases to reflect clinical practice is that although megestrol is listed as a cancer drug by code in the PDTS database, it is not used for nonendometrial or gynecologic cancers. However, because of the PDTS database classification, megestrol is classified as a cancer drug in this retrospective review.

This retrospective review found no significant DDIs for erlotinib or gefitinib, with 1 antidepressant taken by 1 patient for each respective treatment. The degree of inhibition and induction for escitalopram and trazodone are categorized as weak, minimal, or none; therefore, while 1:1 DDIs might be little or no effect, 1:1:1 combination DDIs could have a different outcome. This retrospective data collection cannot be linked to the in vitro hepatocyte DDIs from erlotinib and gefitinib in previous studies.51,52

CONCLUSIONS
This retrospective study describes erlotinib and gefitinib use in the MHS and their potential for DDIs. Because of military service requirements, people who are qualified to serve must be healthy or have either controlled or nonactive medical diagnoses and be physically fit. Consequently, our patient population had fewer common medical illnesses, such as diabetes and obesity, compared with the general population. Most noncancer drugs mentioned in this study are not known CYP metabolizers; therefore, recorded AEs alone cannot conclusively determine whether there is a DDI among erlotinib or gefitinib and noncancer drugs. Antidepressants generally are safe but have boxed warnings in the US for increased risk of suicidal ideation in young people.53,54 This retrospective study did not find statistically significant DDIs for erlotinib or gefitinib with antidepressants. Based on this retrospective data analysis, future in vitro testing is needed to assess DDIs for erlotinib or gefitinib and cancer or noncancer drugs identified in this study.

Acknowledgments
The Department of Research Program funds at Walter Reed National Military Medical Center supported this protocol. We sincerely appreciate the contribution of data extraction from the Joint Pathology Center teams (Francisco J. Rentas, John D. McGeehen, Kimberly M. Greenfield, Beatriz A. Hallo, and Johnny P. Beason) and the MHS database personnel (Maj Ryan Costantino, Lee Ann Zarzabal, Brandon Jenkins, and Alex Rittel). We gratefully thank you for the protocol support from the Department of Research programs: CDR Wesley R. Campbell, CDR Ling Ye, Yaling Zhou, Elizabeth Schafer, Robert Roogow, Micah Stretch, Diane Beaner, Adrienne Woodard, David L. Evers, and Paula Amann.

Author affiliations
-Walter Reed National Military Medical Center, Bethesda, Maryland
-Fort Belvoir Community Hospital, Virginia

Author disclosures
The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner. The authors report no actual or potential conflicts of interest or outside sources of funding with regard to this article.

ETICS and consent
The study protocol was approved by the Walter Reed National Military Medical Center Institutional Review Board and complied with the Health Insurance Portability and Accountability Act as an exempt protocol.

References
2. Xu ZY, Li JL. Comparative review of drug-drug interac-
Drug Interactions


20. Jack MT. Erlotinib. xPharm: The comprehensive pharma-


22. Xeloda (capecitabine). Prescribing Information. Hoff-

23. Paraplatin (carboplatin). Prescribing Information. Bris-


25. Megace (megestrol). Prescribing Information. Par Pharma-

26. Taxol (paclitaxel). Prescribing Information. BASF Aktien-


29. Tagrisso (Osimertinib). Prescribing Information. Astra-


35. Sofran (ondansetron). Prescribing Information. GlaxoS-

36. Percocet (Oxycodone and Acetaminophen). Prescribing
Drug Interactions


Can't attend the poster presentations? Find all the abstracts in your mailbox and online at mdeadge.com/fedprac/avaho

2023 Annual Meeting Posters/Abstracts
September 29 - October 1
Sheraton Grand Chicago

AVACHO
ASSOCIATION OF VA HEPATOLOGY/Oncology

S34 • FEDERAL PRACTITIONER SPECIAL ISSUE • AUGUST 2023